Fundraising FoxBoulder Ventures — 2015 Investments
4 investments dated 2015 · listed companies and verified rows first · show all
miRagen Therapeutics is a biopharmaceutical company developing monoclonal antibodies and other engineered protein therapeutics targeting specific receptors (IGF-1R, FcRn, and TSHR) for autoimmune and rare diseases including thyroid eye disease, Graves' disease, and various autoimmune conditions.
BiotechHealthtechBoulder, US
William S. Marshall(Executive Officer, Director)Jason A. Leverone(Executive Officer)inDavid Rodman(Executive Officer)Stephen Mahoney(President, Chief Executive Officer and Director)Thomas Beetham(Chief Operating Officer)inRadhika Tripuraneni(Chief Medical Officer)in
Board seatKyle Lefkoff· per SEC Form D
Co-investorsBrace PharmaBroadview VenturesJAFCO GroupMC Healthcare VenturesRidgeback CapitalRoche Venture Fund+3 more
Datavail provides managed database administration, applications support, business intelligence, and process automation services for enterprise organizations.
AI & Machine LearningCloud ComputingData & InfrastructureEnterprise SoftwareSaaSBroomfield, US
Andrew Evans(Executive Officer)inMark Perlstein(Executive Officer, Director)David Boyle(Executive Officer)in
BoardJack Tankersley(Director)Susan Bihler(Director)in
Board seatPeter Roshko· per SEC Form D
Co-investorsCatalyst InvestorsLead Edge Capital
Oruka is a biopharmaceutical company developing monoclonal antibodies for plaque psoriasis, psoriatic arthritis, and other dermatologic and inflammatory conditions, aiming for high rates of disease clearance with as few as one or two doses per year.
BiotechWestminster, US
Michael R. Bristow(Executive Officer, Director)Thomas A. Keuer(Executive Officer)Brian L. Selby(Executive Officer)inPatrick M. Wheeler(Executive Officer)Christopher D. Ozeroff(Executive Officer)
BoardDan J. Mitchell(Director)
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.